Targeting nanocarriers containing antisense oligonucleotides to cancer cell

Publication date: Available online 9 December 2016
Source:Journal of Drug Delivery Science and Technology
Author(s): Parth Patel, Y.K. Grawal
Treatment of cancer is a furtive problem in the current era in spite of significant advancement in drug delivery systems and identification of new therapeutic molecules. The ration of lab to market translation of therapeutic research is quite low in anticancer therapy due to hidden and unnameable disease causing and disease progression mechanisms. Oncogene activation disturbs normal cell processes such as cell growth and apoptosis, which ultimately leads to cancer. Different ways, such as RNAi, antisense oligonucleotides, Translation suppressing oligonucleotide and external guide sequences which silences oncogenes are key techniques under investigation currently. The emerging way of formulating nanoparticles containing antisense oligonucleotides and the targeting approaches is illustrated with the brief information on key materials used for the same purpose. Gene targets identified and investigated by various companies and research groups are enumerated and reviewed for their potential to consider antisense gene therapy. Nanocarrier systems which have been reported to enhance feasibility of selective antisense oligonucleotides to treat the disease are assessed for their pros and cons.

Graphical abstract

http://ift.tt/2hnBJoO